News
MIST
0.9655
-1.49%
-0.0146
Weekly Report: what happened at MIST last week (0831-0904)?
Weekly Report · 09/07 09:11
Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals
NASDAQ · 09/04 14:09
Milestone Wins China Approval for Etripamil Nasal Spray
TipRanks · 09/03 22:52
Milestone Pharmaceuticals Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Dow Jones · 09/03 16:04
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $8 Price Target
Benzinga · 09/03 15:54
Milestone Gets China Approval For Etripamil Nasal Spray
NASDAQ · 09/03 15:19
Analysts’ Top Healthcare Picks: Milestone Pharmaceuticals (MIST), Labcorp Holdings (LH)
TipRanks · 09/03 14:50
Milestone Wins NMPA Approval For Etripamil Nasal Spray In PSVT
NASDAQ · 09/03 14:31
Milestone Pharma Announces Approval Of Etripamil Nasal Spray In China; Triggers Milestone Payment
NASDAQ · 09/03 13:57
Milestone Pharmaceuticals announces NMPA approval of etripamil for PSVT
TipRanks · 09/03 13:40
Milestone Pharmaceuticals Says China’s National Medical Products Administration Approves Etripamil Nasal Spray For Treatment Of Paroxysmal Supraventricular Tachycardia In Adults
Benzinga · 09/03 13:36
Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
Barchart · 09/03 08:35
Weekly Report: what happened at MIST last week (0824-0828)?
Weekly Report · 08/31 09:12
Milestone Pharmaceuticals Presenting Data In Moderated EPoster Session Titled 'he Impact of PSVT on Patients’ Daily Life and QoL in Between Episodes' At European Society Of Cardiology Congress 2026
Benzinga · 08/27 12:01
Weekly Report: what happened at MIST last week (0817-0821)?
Weekly Report · 08/24 09:13
Milestone Pharmaceuticals enrolls first patient in ReVeRA-301 pivotal trial
TipRanks · 08/21 12:20
Milestone Initiates Phase 3 Trial Of Etripamil For Self-Administered AFib-RVR Treatment
NASDAQ · 08/21 12:18
Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
Barchart · 08/21 07:00
This Sphere Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga · 08/20 11:51
Cantor starts Milestone Pharmaceuticals at Overweight, sees 200% upside
TipRanks · 08/20 11:00
More
Webull provides a variety of real-time MIST stock news. You can receive the latest news about Milestone Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About MIST
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.